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However, there is likely to be extreme var-
iation in the heterogeneity of such rare
mutations in human SLE. Although rare
protective genetic variants in SLE proba-
bly exist in human SLE, it will not be pos-
sible to prove their existence in the ab-
sence of a complete predictive model of
disease.
Progress in identifying disease-suscep-
tibility genes in SLE is entering an expo-
nential phase of productivity. The advent
of genome-wide association studies in
humans has the potential to reveal the
majority of the main disease-susceptibil-
ity-gene effects that are related to rela-
tively common variants in the human
genome. These approaches have been
highly successful in a number of autoim-
mune diseases. Thus, to some extent,
the primary vehicle for disease-gene dis-
covery has moved away from animal
models and back to man. The results of
these genome-wide analyses, and those
higher-density scans that will undoubt-
edly follow, will allow the assembly of
the basic genetic components of SLE
and other autoimmune diseases, if suffi-
cient sample sizes can be gathered. The
question of the relevance of murine lupus
to human SLE might then be more readily
addressed. However, identifying large
numbers of rare predisposing variants in
human SLE awaits further reduction in
the costs of DNA sequencing, and identi-
fying rare protective variants, analogous
to Coro1aLmb3 mutation is not attainable
at present.
The field of SLE genetics is poised to
yield up its main secrets. The process of
evaluating all the pathogenic implications
is an exciting and immediate prospect.
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In this issue, Sun et al. (2008) model the interface between a neutralizing antibody and HIV-1 glycoprotein 41
(gp41) envelopepeptide in lipids. Thismodel could help overcomea roadblock inHIV-1 vaccine development.The development of a safe and effective
HIV-1 vaccine is one of the highest scien-
tific priorities. One of the many road-
blocks to AIDS vaccine development is
the inability of the HIV-1 cell-surface en-
velope-protein complex (HIV-1 Env) to in-
duce broadly neutralizing antibodies. The
HIV-1 envelope-protein complex consists
of two covalently linked glycoprotein (gp)
components, the outer gp120 piece and
the gp41 component that connects with
a transmembrane domain [reviewed in
(Eckert and Kim, 2001; Haynes and Mon-
tefiori, 2006)]. HIV-1 Env glycoproteins
have conserved functional regions to
which broadly neutralizing antibodies
could, in theory, bemade. However, these10 Immunity 28, January 2008 ª2008 Elsevieregions are poorly immunogenic and hu-
man monoclonal antibodies (mAbs) that
are broadly neutralizing have only rarely
been isolated. Three rare gp41 mem-
brane-proximal external-region neutraliz-
ing antibodies have, however, been de-
rived from either immortalized B cell lines
(mAbs 2F5 and 4E10) or from a bone-mar-
row phage-display library (mAb Z13) from
HIV-1-infected patients (Ofek et al., 2004;
Cardoso et al., 2005; Nelson et al., 2007).
In this issue of Immunity, Sun et al.
(2008) have performed a structural analy-
sis of the gp41 membrane-proximal ecto-
domain region in the context of lipids and
provide the most detailed structural pic-
ture to date of how the membrane-prox-r Inc.imal neutralizing antibody 4E10 might
act. An understanding of how neutralizing
antibodies bind to membrane-proximal-
region epitopes could help us understand
why such antibodies are not routinely
made and could lead to strategies for
optimal HIV-1 vaccine design.
One reason why membrane-proximal
neutralizing antibodies are not routinely
made in humans might come from the
remarkable changes the gp41 undergoes
after binding of gp120 to receptor and
coreceptors on CD4+ T cells. These
receptor-binding-induced conformational
changes in HIV-1 Env gp41 result in viral-
host cell membrane fusion that is brought
about by the conversion of the native
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PreviewsFigure 1. The Three-Step Process of Neutralizing Antibody 4E10 Binding to HIV-1 Envelope Membrane-Proximal Region
According to the model of Sun et al. (2008), the HIV-1 Envelope (HIV-1 Env) gp41 membrane-proximal region in lipids consists of C- and N-terminal helices
connected via a short hinge ‘‘kink’’ (represented by the line between each helix) with the N-terminal helix projected away from the membrane and the kink
and C-terminal helix bound in lipid. The binding of 4E10 to HIV-1 Env gp41 may occur in three steps. In the first step, interaction of hydrophobic residues of
4E10 CDRH3 (third complementarity-determining region of heavy chain) with membrane lipids concentrates 4E10 in close proximity to HIV-1 Env gp41 mem-
brane-proximal region. In the second step, 4E10 encounters membrane-bound gp41 antigen, which might involve initial contacts with exposed gp41 residues
N671 and W680. Next, 4E10 hydrophobic residues (CDRH2 and CDRH3) facilitate conformational rearrangements of the gp41 membrane-proximal region, which
involve peptide side-chain rearrangements, and exposure of key residues (W672, F673). Finally, in the third step, stable docking of 4E10 follows insertion of the
exposed residues of gp41 into 4E10-binding pocket.gp41 membrane-proximal region struc-
ture into a postfusion structure (6-helix
bundle) [(Weissenhorn et al., 1997) re-
viewed in (Eckert and Kim, 2001; Haynes
and Montefiori, 2006)]. The notion is
that the prereceptor-bound gp41 mem-
brane-proximal region is not optimally
exposed, whereas the postfusion state
(6-helix bundle) assumes a structure un-
able to induce neutralizing antibodies. It
might be only the transiently expressed
intermediate form (prehairpin intermedi-
ate) that is the relevant immunogenic
gp41 membrane-proximal structure (Eck-
ert and Kim, 2001).
An alternative reason membrane-proxi-
mal neutralizing antibodies are not
made might be because of their unusual
properties. They have long, hydropho-
bic third-complementarity-determining re-
gions (CDR3s) (Ofek et al., 2004; Cardoso
et al., 2005) and CDR3 arginines asso-
ciated with autoantigen binding (Alam
et al., 2007) and exhibit polyreactivity
with lipids andother autoantigens (Haynes
et al., 2005). It has been suggested that
immune tolerance might play a role in
limiting production of similar antimem-
brane-proximal antibody induction (Hay-
nes et al., 2005). Indeed, human anti-
bodies with long, hydrophobic CDR3s
and/or high affinity for lipids are either de-
leted or undergo receptor editing in bone
marrow (Meffre et al., 2001). That the lipid
reactivity of both 2F5 and 4E10 mAbs
might be required for HIV-1 neutralizationcomes from the observation that both an-
tibodies use a two-step mode of interact-
ing with gp41 peptide-lipid complexes,
encountering lipid initially and inducing
conformation changes in the gp41 mem-
brane-proximal region that allows high-
affinity antibody docking to the lipid-pep-
tide complex (Alam et al., 2007). Thus,
HIV-1 might have evolved an escape
mechanism from some neutralizing anti-
bodies, wherein one of its main Achilles’
heels resembles self-antigens and/or re-
quires lipid reactivity of antibody to bind
and neutralize HIV-1.
The paper by Sun et al. (2008) uses
nuclear magnetic resonance and other
structural-analytic methods to provide
a detailed mechanistic insight on how
4E10 mAb might bind to neutralizing epi-
topes on the membrane-proximal region
of HIV-1 Env. In the model summarized
in Figure 1, the mAb 4E10 first binds virion
lipid and then encounters the membrane-
embedded membrane-proximal peptide.
A gp41 membrane-proximal ectodomain
region (MPER) conformational change is
induced, resulting in the 4E10 mAb’s ex-
tracting the full gp41 epitope from its lipid
environment, and the CDR3H and the
CDR2H 4E10 loops additionally anchor
on the lipid of the virion (Figure 1). This
model highlights several unique proper-
ties of the 4E10 mAb when it binds to
the gp41 MPER epitope on the viral sur-
face. The ability of 4E10 mAb to interact
with lipid and peptide residues providesImmundistinct advantages for the mAb when it
interacts with the gp41 MPER epitope
embedded in a lipid environment. First,
the hydrophobic CDR2H and CDR3H
loops would allow 4E10 a kinetic advan-
tage in forming a high local concentration
of the mAb on the viral surface, thereby
bringing the mAb in close proximity to its
antigen. Because the gp41MPER neutral-
izing epitopes are likely to be more
exposed in the receptor-coreceptor-in-
duced prehairpin-intermediate structure,
which might be only transiently available
for stable binding, there is likely a short
window of opportunity for 4E10 mAb to
bind to its antigen. Second, as described
by Sun et al. (2008), some of the hydro-
phobic residues within the core epitope
of the 4E10-binding site might be buried
in the lipid environment and not initially
available for stable docking of 4E10.
Thus, at the encounter-step (second
step, Figure 1) stage, interaction with
membrane lipids is required to perturb
the local lipid environment and to induce
conformational rearrangements, expose
key residues, and ensure stable docking
of 4E10. At the encounter step, simulta-
neous binding of 4E10 to antigen (tomain-
tain initial contacts) and the interaction of
the 4E10 CDR3 loop with lipid is required.
This suggests that the hydrophobic tip of
MPERmAbCDR3might bemore involved
in antigen binding than what has been
described from crystal-structure studies
(Ofek et al., 2004; Cardoso et al., 2005).ity 28, January 2008 ª2008 Elsevier Inc. 11
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to interact with both lipid and gp41 might
be one of the key features of anti-HIV-1
gp41 neutralizing antibodies that distin-
guish them from nonneutralizing mAbs
that bind at or close to the gp41 MPER
neutralizing epitopes (Alam et al., 2007).
One cautionary note, however, is that
although the structural studies of Sun
et al. (2008) are with model peptide-lipid
complexes, including those mimicking
the viral-lipid composition, the structures
of the interface of 4E10 mAb with native
virions are yet to be shown.
Most important for HIV-1 vaccine re-
search, Sun et al. propose a strategy for
overcoming the poor immunogenicity of
the 4E10 gp41 epitope by constructing a
correct gp41 structure on a lipid-coated
nanoparticle (Sun et al., 2008). The hope
is that by focusing the immune response
on only those amino acids exposed on
the surface of the helical regions (N671,
N674, N677, and W680), one could per-
haps induce nonpolyreactive neutralizing
antibodies.
Two fundamental questions for HIV-1
vaccinologists remain. Are neutralizing
antibodies to the gp41 membrane-pro-
ximal region not made because the im-
munogen structure is not correct, or are
gp41 neutralizing antibodies not made
because they are polyreactive and thus
are normally deleted or undergo receptor
editing by B cell tolerance mechanisms?
If the answer to the first question is yes,12 Immunity 28, January 2008 ª2008 Elsevithen it is only a matter of time before
structures of gp41 membrane-proximal
region are designed and synthesized. If
the answer to the second question is
yes, then the solution to the problem will
be more difficult and will require detailed
analysis of the populations of B cells that
have the capacity to make broadly neu-
tralizing antibodies and deciphering of
their activation signals to stimulate them
by envelope-based vaccines. If the an-
swer to both questions is yes, then a solu-
tion to the neutralizing-antibody problem
will require both optimal envelope-epi-
tope structures and formulation in ways
to trigger otherwise tolerized B cells.
Autoreactivity is a normal characteristic
of the human B cell repertoire, and most
autoantibodies and particularly lipid-reac-
tive antibodies are not necessarily patho-
genic. It will be of critical importance to
determine whether membrane-proximal
neutralizing antibodies that are not poly-
specific can be induced, and whether
a neutralizing-antibody response to gp41
can be induced with constructs such as
those suggested by Sun et al. (2008).
It will be good news for the vaccine field
if this and other structural solutions to the
broadly neutralizing-antibody problemare
ultimately successful. It will be far easier to
make a constrained Env structure and
then formulate it with traditional adjuvants
than it will be to work to consistently
break immunologic tolerance to induce
antibodies that are normally deleted. Theer Inc.work of Sun et al. (2008) provides a strat-
egy for gp41-based immunogen designs
that might be capable of inducing broadly
reactive neutralizing antibodies.
REFERENCES
Alam, S.M., McAdams, M., Boren, D., Rak, M.,
Scearce, R.M., Gao, F., Camacho, Z.T., Gewirth,
D., Kelsoe, G., Chen, P., and Haynes, B.F. (2007).
J. Immunol. 178, 4424–4435.
Cardoso, R.M., Zwick, M.B., Stanfield, R.L., Kunert,
R., Binley, J.M., Katinger, H., Burton, D.R., andWil-
son, I.A. (2005). Immunity 22, 163–173.
Eckert, D.M., and Kim, P.S. (2001). Annu. Rev.
Biochem. 70, 777–810.
Haynes, B.F., Fleming, J., St Clair, E.W., Katinger,
H., Stiegler, G., Kunert, R., Robinson, J., Scearce,
R.M., Plonk, K., Staats, H.F., et al. (2005). Science
308, 1906–1908.
Haynes, B.F., and Montefiori, D.C. (2006). Expert
Rev. Vaccines 5, 579–595.
Meffre, E., Milili, M., Blanco-Betancourt, C.,
Antunes, H., Nussenzweig, M.C., and Schiff, C.
(2001). J. Clin. Invest. 108, 879–886.
Nelson, J.D., Brunel, F.M., Jensen, R., Crooks,
E.T., Cardoso, R.M., Wang, M., Hessell, A., Wilson,
I.A., Binley, J.M., Dawson, P.E., et al. (2007).
J. Virol. 81, 4033–4043.
Ofek, G., Tang, M., Sambor, A., Katinger, H.,
Mascola, J.R., Wyatt, R., and Kwong, P.D. (2004).
J. Virol. 78, 10724–10737.
Sun, Z.-Y., Oh, K.J., Kim, M., Yu, J., Brusic, V.,
Song, L., Qiao, Z., Wang, J.-H., Wagner, G., and
Reinherz, E.L. (2008). Immunity 28, this issue,
52–63.
Weissenhorn, W., Dessen, A., Harrison, S.C.,
Skehel, J.J., and Wiley, D.C. (1997). Nature 387,
426–430.
